Last update 01 Jul 2024
TK-112690
Last update 01 Jul 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms METREXASSISTTM, TK 112690, TK-90 |
Target |
Mechanism Uridine phosphorylase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Structure
Molecular FormulaC10H12N2O5 |
InChIKeyWLLOAUCNUMYOQI-JAGXHNFQSA-N |
CAS Registry22423-26-3 |
Related
7
Clinical Trials associated with TK-112690A Phase 2a, Multi-center, Open Label, Dose Optimization, Pilot Study to Assess the Safety and Tolerability at the Maximum Tolerated Dose of Parenteral TK-112690 in Non-Metastatic Squamous Cell Carcinoma of Head and Neck Patients Scheduled to Receive Chemoradiation. - NIL
A Phase 2a, multi-center, placebo-controlled, randomized, assessor blind study ofbolus 5-fluorouracil and infused leucovorin plus either infused TK 90 for parenteral use or infused TK 90 placebo administered weekly for 6 consecutive weeks to patients with colorectal cancer.
A Phase 2a, multi-center, placebo-controlled, randomized, assessor-blind study to assess the safety & efficacy of parenteral TK-90 or parenteral TK-90 placebo administered daily to Patients scheduled to receive radiotherapy for non-metastatic squamous cell carcinoma of the head and neck (SCCHN). - TOSK 0004
100 Clinical Results associated with TK-112690
Login to view more data
100 Translational Medicine associated with TK-112690
Login to view more data
100 Patents (Medical) associated with TK-112690
Login to view more data
100 Deals associated with TK-112690
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| radiation oral mucositis | Phase 2 | IN | 17 Jun 2022 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 2 | IN | 17 Jun 2022 | |
| Colorectal Cancer | Phase 2 | IN | 15 Jun 2022 | |
| Mucositis | Phase 2 | US | 20 Jul 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 22 | (TK112690) | djfjpgajml(dvratluyux) = nilqzmlull ijrmebbjas (gzfbrafzva, ymtfjdafer - zqfsluflcg) View more | - | 03 Jun 2021 | ||
Placebo TK-112690 (Placebo) | djfjpgajml(dvratluyux) = osqrhbbywq ijrmebbjas (gzfbrafzva, dmsoeiczkf - uibqsxmkqo) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free